NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CGEN

Compugen Ltd

Apr 23 • 04:00PM ET

1.44

Dollar change -0.02
Percentage change -1.37	%

Healthcare • Biotechnology • Israel • NASD

Peers: MRNA VRTX ALLO CRSP FATE NTLA EDIT SGMO BLUE CLLS

| Held by: SPDW GWX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.16	Insider Own	2.12%	Shs Outstand	93.51M	Perf Week	4.35%
Market Cap	134.66M	Forward P/E	-	EPS next Y	-0.10	Insider Trans	0.00%	Shs Float	91.53M	Perf Month	-11.11%
Income	-14.23M	PEG	-	EPS next Q	-0.06	Inst Own	14.31%	Short Float	2.12%	Perf Quarter	-39.50%
Sales	27.86M	P/S	4.83	EPS this Y	35.42%	Inst Trans	10.85%	Short Ratio	4.62	Perf Half Y	-15.79%
Book/sh	0.61	P/B	2.35	EPS next Y	6.45%	ROA	-12.04%	Short Interest	1.94M	Perf Year	-24.21%
Cash/sh	1.10	P/C	1.30	EPS next 5Y	29.25%	ROE	-23.63%	52W Range	1.13 - 2.66	Perf YTD	-5.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.03%	ROI	-24.80%	52W High	-45.86%	Beta	2.55
Dividend TTM	-	Quick Ratio	5.26	Sales past 5Y	110.88%	Gross Margin	71.54%	52W Low	27.43%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	5.26	EPS Y/Y TTM	26.35%	Oper. Margin	-53.44%	RSI (14)	48.08	Volatility	6.38% 7.45%
Employees	74	Debt/Eq	0.05	Sales Y/Y TTM	-16.72%	Profit Margin	-51.07%	Recom	1.00	Target Price	4.00
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-162.15%	Payout	-	Rel Volume	0.28	Prev Close	1.46
Sales Surprise	-88.70%	EPS Surprise	-315.38%	Sales Q/Q	-95.60%	Earnings	Mar 04 BMO	Avg Volume	419.54K	Price	1.44
SMA20	3.90%	SMA50	-13.16%	SMA200	-18.43%	Trades		Volume	117,978	Change	-1.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-13-25	Initiated	Oppenheimer	Outperform	$4
Aug-05-22	Downgrade	Jefferies	Buy → Hold	$2
May-26-20	Resumed	JMP Securities	Mkt Outperform	$18
May-13-20	Initiated	Stifel	Buy	$19
May-07-20	Initiated	SVB Leerink	Outperform
Apr-22-20	Initiated	ROTH Capital	Buy	$28
Mar-24-20	Initiated	SunTrust	Buy	$16
Jan-16-20	Initiated	Cantor Fitzgerald	Overweight	$10
Mar-29-18	Initiated	Oppenheimer	Outperform
Feb-01-16	Resumed	Oppenheimer	Outperform
Oct-15-15	Initiated	FBR Capital	Outperform	$14
Apr-23-15	Resumed	Jefferies	Buy	$11
Apr-21-15	Initiated	Oppenheimer	Outperform	$11
Feb-07-14	Initiated	MLV & Co	Buy	$14
Dec-28-09	Reiterated	Cantor Fitzgerald	Buy	$5 → $12
Jul-29-09	Initiated	Cantor Fitzgerald	Buy	$6.50

Show Previous Ratings

Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-26-25 07:00AM	Compugen to Participate in Multiple Virtual Investor Conferences in April 2025 (PR Newswire)
Mar-23-25 08:29AM	Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-05-25 02:04AM	Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) +7.74%
Mar-04-25 08:15AM	Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.18%
08:15AM	Loading…
08:15AM	Compugen Reports Fourth Quarter and Full Year 2024 Results (PR Newswire)
07:22AM	Compugen: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	/C O R R E C T I O N -- Compugen Ltd./ (PR Newswire)
Mar-03-25 07:00AM	Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference (PR Newswire) -5.73%
Feb-26-25 07:00AM	Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen with Ultima Genomics' Single Cell Genomics Sequencing Technology (PR Newswire)
Feb-18-25 07:00AM	Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025 (PR Newswire)
Feb-04-25 07:00AM	Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-08-25 07:00AM	Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors (PR Newswire)
Nov-27-24 07:00AM	Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies (PR Newswire) +5.92%
Nov-13-24 02:08AM	Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... (GuruFocus.com)
11:05AM	Loading…
Nov-12-24 11:05AM	Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates (Zacks) -8.05%
09:56AM	Compugen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Third Quarter 2024 Results (PR Newswire)
Nov-11-24 07:00AM	Compugen to Participate in Stifel 2024 Healthcare Conference (PR Newswire)
Nov-05-24 09:00AM	Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 (PR Newswire)
Oct-29-24 07:00AM	Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (PR Newswire)
Oct-07-24 07:00AM	Compugen to Present New Clinical Data at SITC 2024 (PR Newswire)
Sep-11-24 12:00PM	Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Sep-09-24 07:00AM	Compugen to Present at Single Cell Genomics 2024 Conference (PR Newswire) +8.20%
Aug-29-24 07:00AM	Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +6.84%
Aug-26-24 12:20PM	Can Compugen (CGEN) Run Higher on Rising Earnings Estimates? (Zacks)
Aug-06-24 08:25AM	Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:22AM	Compugen: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Second Quarter 2024 Results (PR Newswire)
Jul-30-24 06:52AM	Compugen receives FDA approval for Phase I trial of solid tumour treatment (Clinical Trials Arena)
07:00AM	Loading…
Jul-29-24 07:00AM	Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors (PR Newswire)
Jul-23-24 07:00AM	Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 (PR Newswire)
Jun-17-24 07:00AM	Compugen to Present at Upcoming Antibody Industrial Symposium (PR Newswire) -5.31%
Jun-04-24 09:55AM	Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
May-30-24 07:00AM	Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig (PR Newswire) -7.98%
May-21-24 08:08AM	Compugen Ltd. (NASDAQ:CGEN) Q1 2024 Earnings Call Transcript (Insider Monkey) +6.90%
May-20-24 11:52AM	CGEN Stock Earnings: Compugen Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -17.54%
08:10AM	Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:07AM	Compugen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports First Quarter 2024 Results (PR Newswire)
May-16-24 07:00AM	Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential (PR Newswire)
May-15-24 09:57AM	Compugen Names David Silberman CFO (MT Newswires) +5.74%
07:00AM	Compugen Appoints David Silberman as Chief Financial Officer (PR Newswire)
May-06-24 07:00AM	Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 (PR Newswire)
Apr-25-24 07:00AM	Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 (PR Newswire)
Apr-10-24 07:00AM	Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 (PR Newswire)
Apr-03-24 07:00AM	Compugen to Participate in Two Upcoming Investor Conferences (PR Newswire)
Mar-12-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice (Zacks)
Mar-11-24 07:00AM	Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy (PR Newswire) -5.44%
Mar-07-24 09:41AM	Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 07:00AM	Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 (PR Newswire)
Mar-05-24 11:53AM	CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -13.56%
07:16AM	Compugen: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Fourth Quarter and Full Year 2023 Results (PR Newswire)
Feb-29-24 08:58AM	Is a Surprise Coming for Compugen (CGEN) This Earnings Season? (Zacks)
Feb-26-24 07:00AM	Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 (PR Newswire) +9.40%
Feb-21-24 12:00PM	Compugen (CGEN) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-20-24 07:00AM	Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 (PR Newswire)
Feb-15-24 07:00AM	Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer (PR Newswire)
Jan-08-24 07:05AM	Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer (PR Newswire) +6.86%
07:00AM	Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Dec-19-23 10:11AM	Why Is Compugen (CGEN) Stock Up 189% Today? (InvestorPlace) +173.97%
07:10AM	Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer (PR Newswire)
07:05AM	Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology (PR Newswire)
07:00AM	Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program (Business Wire)
Dec-15-23 08:17AM	7 Promising Penny Stocks With the Potential to Defy Expectations (InvestorPlace)
Dec-05-23 09:40AM	Is Compugen (CGEN) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-08-23 04:41PM	Compugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.93% -7.23%
Nov-07-23 07:28AM	Compugen: Q3 Earnings Snapshot (Associated Press Finance) -5.85%
07:00AM	Compugen Reports Third Quarter 2023 Results (PR Newswire)
Nov-06-23 07:00AM	Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy (PR Newswire)
Nov-03-23 04:35PM	Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
Oct-31-23 09:00AM	Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer (PR Newswire) +10.95%
Oct-24-23 07:00AM	Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023 (PR Newswire) +6.44%
Oct-03-23 07:00AM	Compugen to Present at Single Cell Genomics 2023 Meeting (PR Newswire)
Oct-02-23 07:00AM	Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer (PR Newswire)
Sep-27-23 09:00AM	Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023 (PR Newswire)
Sep-14-23 09:40AM	Is Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-31-23 07:00AM	Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-29-23 09:40AM	Has Compugen (CGEN) Outpaced Other Medical Stocks This Year? (Zacks)
Aug-10-23 12:13PM	Compugen Ltd. (NASDAQ:CGEN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-07-23 07:17AM	Compugen: Q2 Earnings Snapshot (Associated Press Finance) -8.04%
07:00AM	Compugen Reports Second Quarter 2023 Results (PR Newswire)
Jul-24-23 07:00AM	Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023 (PR Newswire) -5.88%
Jul-17-23 07:00AM	Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party (PR Newswire)
Jun-22-23 07:00AM	Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study (PR Newswire) -7.89%
Jun-13-23 07:00AM	Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Jun-05-23 07:00AM	Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer (PR Newswire) +6.67%
Jun-02-23 07:09AM	We Think Compugen (NASDAQ:CGEN) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-25-23 10:49AM	Cathie Wood is Selling These 12 Stocks in 2023 (Insider Monkey)
May-18-23 09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks)
May-15-23 07:10AM	Compugen: Q1 Earnings Snapshot (AP Finance) +10.02%
07:00AM	Compugen Reports First Quarter 2023 Results (PR Newswire)
May-11-23 07:00AM	Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023 (PR Newswire)
May-09-23 07:00AM	Compugen to Present at the JMP Securities Life Sciences Conference (PR Newswire)
May-01-23 07:00AM	Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023 (PR Newswire)
Apr-27-23 07:00AM	Compugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023 (PR Newswire)
Apr-26-23 07:00AM	Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting (PR Newswire)
Mar-15-23 07:00AM	Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023 (PR Newswire)
Mar-14-23 09:40AM	Is Certara (CERT) Outperforming Other Medical Stocks This Year? (Zacks)

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGEN

Compugen Ltd

Upgrade your FINVIZ experience